Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This study found that targeting IL-6, IL-1, and CCR6 signaling pathways may effectively reduce irradiation-induced alopecia and dermatitis in radiotherapy patients.

This research highlights advancements in understanding and treating psoriasis, finding that targeted therapies like IL-17 and IL-23 inhibitors show promise, but challenges such as adverse events, treatment resistance, and the need for personalized approaches remain.

This study found that overexpression of miR-1246 in peripheral CD4+ T cells can reduce markers associated with inflammation and T cell activation in severe active alopecia areata, suggesting potential therapeutic benefits.

This study highlights the evolving understanding of acne's pathophysiology and suggests that targeting pro-inflammatory cytokines such as IL-1β, IL-17, IL-23, and TNFα with biological antibodies may offer new treatment strategies for severe acne and its scars.

This study found that Punica granatum ethanolic leaf extract may alleviate skin fibrosis in rats by modulating inflammation-related pathways and reducing dermal alterations.

This study found that EGFR and MEK inhibitors may induce acneiform skin toxicities by interacting with the skin bacterium Cutibacterium acnes to increase IL-36γ and IL-8 production in keratinocytes.

This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.

This study found that alopecia areata patients had higher baseline interleukin levels, which significantly decreased with tofacitinib treatment, though this change did not correspond to disease severity improvement.

In this study, researchers found that using a 5-α reductase inhibitor may reduce inflammation-related cytokines associated with T-helper cell 1 and T-helper cell 2 in prostate tissues after surgery, but it did not affect those related to Th17 cells.

In this mini-review, recent insights suggest a possible role of type-2-related immunity in diseases like alopecia areata, vitiligo, and localized scleroderma, though whether this immune response benefits or worsens these conditions remains unclear.

This study observed that Epigallocatechin-3-gallate (EGCG) can inhibit phosphorylation of STAT1 and reduce a specific subset of immune cells in vitro and ex vivo, suggesting a potential role in maintaining immune privilege in alopecia areata.

This study found that IL-17A-producing γδ T cells play a key role in bone fracture healing by promoting bone formation, with deficiencies leading to impaired repair in mice.

In this animal study, finasteride significantly improved autism-like symptoms in rats by reversing biochemical markers and enhancing behaviors, potentially due to its antioxidant and anti-androgen effects.

Hair follicles are crucial for maintaining skin barrier function.

This review synthesizes current evidence on therapies for dissecting cellulitis of the scalp, noting that biologics show promise for treatment-resistant cases, though systemic retinoids remain the first-line therapy.

This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.

This study suggests that Cepharanthine, a monomer in traditional Chinese medicine, may help treat COVID-19 by affecting multiple signaling pathways, and that TNF and IL-17 inhibitors used in rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis might also be beneficial.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.

This research notes that biologics and small molecules are effective for treating nail psoriasis and alopecia areata, albeit with precautions for adverse events, but no clinical trials have been published for their use in treating nail lichen planus and atopic dermatitis.

This study found that patients with alopecia areata and their healthy family members had elevated levels of Th1- and Th17-related cytokines, suggesting a genetic link in cytokine dysregulation.

This literature review explores the role of biomarkers in personalized medicine for various dermatological conditions like Hidradenitis Suppurativa, Psoriasis, and Atopic Dermatitis, highlighting how they guide targeted therapies and the limitations of current markers in specificity, as reported by the authors.

This study identified Th22 cells as key effectors in hair regeneration driven by thymosin beta 15, suggesting they could be potential targets for hair regrowth therapies.

This study found that hair follicles play a significant role in regulating skin barrier function, with disruptions in the upper hair follicle affecting the epidermis, influencing processes like desquamation and sebum release, and leading to cell movement into the epidermis.

This study found that chronic low-grade inflammation exists independently of excess weight or obesity in women with PCOS, with notable increases in specific cytokines such as IL-9, MCP-3, and MIP-1α.

This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.

This review discusses recent advancements in therapies for ichthyosis, highlighting promising prospects in protein replacement and gene therapy, but it reports no new clinical results.

This study found that administering dupilumab to patients with moderate-to-severe atopic dermatitis over 12 weeks altered both fungal and bacterial skin microbiomes, increasing microbial diversity and decreasing colonization by Malassezia and Staphylococcus aureus at lesion sites.

This review examines the interconnected processes of atopic dermatitis and alopecia areata, highlighting shared immune imbalances, genetic factors, and microbiome influences, while analyzing current and emerging treatments and identifying gaps in understanding these overlapping conditions.